Morningstar Investment Management LLC lifted its position in CME Group Inc. (NASDAQ:CME - Free Report) by 28.0% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 9,396 shares of the financial services provider's stock after purchasing an additional 2,055 shares during the period. Morningstar Investment Management LLC's holdings in CME Group were worth $2,493,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently made changes to their positions in CME. Wayfinding Financial LLC bought a new stake in CME Group in the first quarter valued at $25,000. Cornerstone Planning Group LLC boosted its holdings in CME Group by 122.2% in the first quarter. Cornerstone Planning Group LLC now owns 100 shares of the financial services provider's stock valued at $26,000 after acquiring an additional 55 shares in the last quarter. New Age Alpha Advisors LLC boosted its holdings in CME Group by 50.0% in the fourth quarter. New Age Alpha Advisors LLC now owns 129 shares of the financial services provider's stock valued at $30,000 after acquiring an additional 43 shares in the last quarter. Golden State Wealth Management LLC boosted its holdings in CME Group by 612.5% in the first quarter. Golden State Wealth Management LLC now owns 114 shares of the financial services provider's stock valued at $30,000 after acquiring an additional 98 shares in the last quarter. Finally, Alpine Bank Wealth Management bought a new stake in CME Group in the first quarter valued at $32,000. Institutional investors own 87.75% of the company's stock.
CME Group Stock Performance
Shares of NASDAQ:CME traded up $2.14 during mid-day trading on Friday, reaching $280.42. 2,084,643 shares of the company traded hands, compared to its average volume of 2,369,980. The company's 50 day moving average price is $276.14 and its 200-day moving average price is $263.55. The firm has a market cap of $101.05 billion, a PE ratio of 27.13, a PEG ratio of 4.93 and a beta of 0.44. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.02 and a quick ratio of 1.02. CME Group Inc. has a 52 week low of $196.62 and a 52 week high of $290.79.
CME Group (NASDAQ:CME - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The financial services provider reported $2.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.91 by $0.05. The company had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.68 billion. CME Group had a return on equity of 14.60% and a net margin of 58.48%. The firm's revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.56 EPS. On average, equities analysts expect that CME Group Inc. will post 10.49 EPS for the current fiscal year.
CME Group Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Wednesday, June 25th. Investors of record on Monday, June 9th were issued a $1.25 dividend. The ex-dividend date of this dividend was Monday, June 9th. This represents a $5.00 dividend on an annualized basis and a yield of 1.8%. CME Group's payout ratio is currently 48.40%.
Insider Buying and Selling
In related news, Director Phyllis M. Lockett sold 1,060 shares of the business's stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $277.88, for a total value of $294,552.80. Following the transaction, the director directly owned 3,108 shares of the company's stock, valued at approximately $863,651.04. The trade was a 25.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Jonathan L. Marcus sold 390 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $277.50, for a total value of $108,225.00. Following the completion of the transaction, the general counsel directly owned 6,708 shares in the company, valued at approximately $1,861,470. This represents a 5.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,400 shares of company stock worth $2,881,130 in the last quarter. 0.30% of the stock is owned by insiders.
Analysts Set New Price Targets
CME has been the topic of several recent analyst reports. Citigroup lifted their price target on shares of CME Group from $265.00 to $275.00 and gave the company a "neutral" rating in a report on Thursday, July 3rd. JPMorgan Chase & Co. lowered their price objective on CME Group from $223.00 to $211.00 and set an "underweight" rating for the company in a research report on Thursday, April 24th. Piper Sandler raised their price objective on CME Group from $283.00 to $296.00 and gave the company an "overweight" rating in a research report on Tuesday, July 15th. Wall Street Zen lowered CME Group from a "hold" rating to a "sell" rating in a research report on Sunday, July 13th. Finally, UBS Group reiterated a "neutral" rating and issued a $305.00 price objective on shares of CME Group in a report on Thursday, July 24th. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $261.93.
Get Our Latest Stock Analysis on CME
CME Group Profile
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
Featured Stories

Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.